The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.